E-LIB Suche - Ergebnisse für: Ameratunga, Malaka

1

A systematic review of the impact of brain tumours on risk ..:

Tran, Sophie ; Lapidus, Adam ; Neal, Andrew...
Journal of Neuro-Oncology. 166 (2024) 3 - p. 395-405 , 2024

Link: https://doi.org/10.1007/..

2

Computational repurposing of oncology drugs through off‐tar..:

Walpole, Imogen R. ; Zaman, Farzana Y ; Zhao, Peinan...
Clinical and Translational Medicine. 14 (2024) 4 - p. , 2024

Link: https://doi.org/10.1002/..

3

Sustained Clinical Response to Immunotherapy Followed by BE..:

Herbison, Harriet ; Davis, Sidney ; Nickless, David..
Journal of Immunotherapy and Precision Oncology. 7 (2024) 1 - p. 67-72 , 2024

Link: https://doi.org/10.36401..

4

Symptomatic brain metastases in melanoma:

Knox, Andrea ; Wang, Tim ; Shackleton, Mark.
Experimental Dermatology. 33 (2024) 4 - p. , 2024

Link: https://doi.org/10.1111/..

5

UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 ab..:

Kuser-Abali, Gamze ; Zhang, Youfang ; Szeto, Pacman...
Oncogene. 42 (2023) 17 - p. 1360-1373 , 2023

Link: https://doi.org/10.1038/..

6

Phase 1, dose-escalation study of guadecitabine (SGI-110) i..:

Papadatos-Pastos, Dionysis ; Yuan, Wei ; Pal, Abhijit...
Journal for ImmunoTherapy of Cancer. 10 (2022) 6 - p. e004495 , 2022

Link: https://doi.org/10.1136/..

7

Dramatic clinical response in the treatment of small cell g..:

Zaman, Farzana Yasmin ; McLean, Catriona ; Ameratunga, Malaka
Journal of Clinical Pharmacy and Therapeutics. 47 (2022) 6 - p. 832-834 , 2022

Link: https://doi.org/10.1111/..

8

A phase 1 safety and bioimaging trial of antibody DS-8895a ..:

Gan, Hui K. ; Parakh, Sagun ; Lee, F. T....
Investigational New Drugs. 40 (2022) 4 - p. 747-755 , 2022

Link: https://doi.org/10.1007/..

9

Tumor volumes as a predictor of response to the anti-EGFR a..:

Gan, Hui K ; Parakh, Sagun ; Lassman, Andrew B...
Neuro-Oncology Advances. 3 (2021) 1 - p. , 2021

Link: https://doi.org/10.1093/..

10

The kinase polypharmacology landscape of clinical PARP inhi..:

Antolin, Albert A. ; Ameratunga, Malaka ; Banerji, Udai...
Scientific Reports. 10 (2020) 1 - p. , 2020

Link: https://doi.org/10.1038/..

11

Combination of BRAF and MEK inhibition in BRAF V600E mutant..:

Yau, Wing Hing ; Ameratunga, Malaka
Journal of Clinical Pharmacy and Therapeutics. 45 (2020) 5 - p. 1172-1174 , 2020

Link: https://doi.org/10.1111/..

12

First-in-human Phase 1 open label study of the BET inhibito..:

Ameratunga, Malaka ; Braña, Irene ; Bono, Petri...
British Journal of Cancer. 123 (2020) 12 - p. 1730-1736 , 2020

Link: https://doi.org/10.1038/..

13

Neutrophil-lymphocyte ratio kinetics in patients with advan..:

Ameratunga, Malaka ; Chénard-Poirier, Maxime ; Moreno Candilejo, Irene...
European Journal of Cancer. 89 (2018) - p. 56-63 , 2018

Link: https://doi.org/10.1016/..

14

CNS cancer immunity cycle and strategies to target this for..:

Ameratunga, Malaka ; Coleman, Niamh ; Welsh, Liam..
Oncotarget. 9 (2018) 32 - p. 22802-22816 , 2018

Link: https://doi.org/10.18632..

15

ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EG..:

Gan, Hui ; Seow, Aidan ; Lau, Eddie...
Neuro-Oncology. 20 (2018) suppl_6 - p. vi24-vi24 , 2018

Link: https://doi.org/10.1093/..